TP-1287 is under clinical development by Sumitomo Dainippon Pharma Oncology and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase I drugs for Ewing Sarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TP-1287 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-1287 is under development for the treatment of ewing sarcoma solid tumor, multiple myeloma, acute myeloid leukemia (AML), androgen-sensitive prostate cancer and hormone refractory (castration resistant, androgen-independent) prostate cancer and triple negative breast cancer. It is a small molecule administered orally. The drug candidate is a prodrug of alvocidib which acts by targeting CDK9.
Sumitomo Dainippon Pharma Oncology overview
Sumitomo Dainippon Pharma Oncology (Sumitomo Dainippon), formerly Boston Biomedical, a subsidiary of Sumitomo Chemical Co Ltd, is a developer of novel therapeutics to treat cancer. The company offers drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, clinical trials, and regulatory affair services. Its drug candidates include BBI608 and BBI503. The company also offers cancer stem cell development programs that include cancer cell stemless, signaling pathways, treatment resistance, recurrence and metastasis; resources and CSC programs. Sumitomo Dainippon is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of TP-1287’s drug-specific PTSR and LoA scores, buy the report here.